ArticleFrontiers in immunology2025
Longitudinal immune profiling uncovers regulatory T cell signatures associated with the progression of COVID-19.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The role of Regulatory T cells (Tregs) in severe COVID-19 remains unclear. Some authors reported that Tregs increased in peripheral circulation, while other investigators reported that these cells decreased in severe COVID-19 patients. The expression of FoxP3 in Tregs remains inconsistent and controversial. These observations have been made using immune phenotyping via flow cytometry and T-cell sequencing; however, none of these data provide a clear indication of what Tregs are doing in this chaotic hyperactivated immune response. Methods: We conducted a comprehensive characterization of the Treg compartment in a longitudinal cohort of patients with acute COVID-19, including individuals with mild or severe disease. Using RNA-seq, we analyzed gene expression across the cohort, while flow cytometry enabled us to determine Treg phenotype and observe changes during disease progression. Furthermore, we assessed Treg activity through a suppression assay. Results: Gene expression analysis revealed significant downregulation of genes involved in regulatory pathways supporting T regs' functional activities, consistent across the severe patients analyzed. In contrast, we found increased expression of these genes in patients with mild disease. This finding was further confirmed by phenotyping analysis, which showed significant differences in CD25 Discussion: Our findings offer critical insights into the role of Tregs in SARS-CoV-2, with implications that extend beyond this viral infection. Understanding how Tregs contribute to immune responses in COVID-19 could inform therapeutic strategies to modulate immune regulation in infectious diseases more broadly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.